Post by PharmaShots

16,868 followers

🎯 π‹πžπšππžπ«π¬π‘π’π© 𝐈𝐧𝐬𝐒𝐠𝐑𝐭 𝐟𝐫𝐨𝐦 Jared Kelly, π‚π„πŽ & πƒπ’π«πžπœπ­π¨π«, Oncolytics Biotech Inc. β€œTo be in the acquisition zone, you need more than clinical data.” In today’s biopharma landscape, strong clinical outcomes are only part of the equation. Strategic positioning, compelling differentiation, commercial readiness, and a clear value story are equally critical when it comes to attracting partners, investors, and acquisition interest. In this insightful conversation with PharmaShots, Jared Kelly shares his perspective on what truly drives biotech value creation and how companies can move beyond data to become attractive acquisition targets. πŸ”Ή What makes a biotech company acquisition-ready? πŸ”Ή Why clinical success alone may not be enough πŸ”Ή Key factors influencing partnership and M&A decisions πŸ”Ή Strategic lessons for emerging biopharma leaders Watch & Listen to the full interview to hear Jared Kelly’s complete insights: ▢️ YouTube: https://lnkd.in/gKXt5ESC πŸŽ™οΈ Spotify: https://lnkd.in/gUmtCU3Q πŸ“° Substack: https://lnkd.in/gdcJuBi6 #PharmaShots #Biotech #Oncolytics #JaredKelly #Biopharma #HealthcareInnovation #LifeSciences #ClinicalDevelopment #BiotechLeadership #MergersAndAcquisitions #PharmaceuticalIndustry #Innovation #Healthcare #PharmaIndustry #BiotechNews #LeadershipInsights

Post content